Cleveland Clinic International IV Robotics Summit

Abstract

Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose The proceedings of an international summit on the current and desired future state of use of robotic systems to compound intravenous (IV) solutions are summarized. Summary The International IV Robotics Summit was held at the Cleveland Clinic main campus in Cleveland, OH, on April 29 and 30, 2019. The purpose of the summit was 2-fold: (1) to define the current state of robotic IV compounding and (2) to develop a guide for automation companies, pharmacy departments, and drug manufacturers to improve the technology and expand the use of IV robotics in health systems in the future. The first day of the summit included 45-minute presentations by each of the speakers. Each lecturer recounted a different hospital’s experience implementing and using IV robotics. On day 2 of the summit, an expert panel dedicated to mapping the future of IV robotics was convened to determine barriers to widespread adoption of IV robotics in health systems and offer potential solutions to remove these barriers. The expert panel targeted 3 specific audiences: robot manufacturers, drug manufacturers, and fellow pharmacy leaders. Conclusion It is the hope of the international faculty that the information that emerged from the summit can be used by others to successfully implement IV compounding robotics in their sterile products areas to maximize patient safety. The summit also served as a call to action for pharmacy leaders, drug manufacturers, and robotic companies to develop a safer, more efficient future for patients by working together to optimize the development and operation of IV robotics.

Evaluation of oncology infusion pharmacy practices: A nationwide survey

“…44,45 There are many key stakeholders in ensuring preparations are capable of being handled through IV robotic systems such as infusion pharmacists and technicians, robotics manufacturers, and pharmaceutical manufacturers to ensure vial usability within the platforms. 45,46 There are some medications in the oncology infusion areas that are unable to be compounded by the available IV robotics systems due to various limitations but sites should continue to work with IV robotics system manufacturers to expand available medications within their libraries.…”

Deviations From Best Practice: Findings From a Certified Patient Safety Organization Remote-Verification Observational Study of Intravenous Compounding of Chemotherapeutic and Ancillary Drugs

“… 25 Consequently, benefits of IV robotics vs manual compounding include precision, accuracy, extensive documentation, safety features, and improved sterility. 26 , 27 Ready-to-administer chemotherapy preparations offer similar advantages in that dosing and final infusion product concentrations are standardized across all preparations, improving patient safety. In a pediatric hospital study of high-alert drugs including adrenergic agents and concentrated electrolyte products, implementation of ready-to-administer infusions allowed these medications to be available in an expedited manner, removed the potential for compounding errors, and ensured the medication was prepared in a sterile environment.…”